Assessing CA125 as a Tumor Marker for Ovarian Cancer
Author Information
Author(s): P.A. Canney, M. Moore, P.M. Wilkinson, R.D. James
Primary Institution: Christie Hospital & Holt Radium Institute
Hypothesis
The study aims to assess the potential of CA125 as a marker for established ovarian cancer.
Conclusion
CA125 is a sensitive marker for ovarian cancer that can reflect disease progression or response to chemotherapy.
Supporting Evidence
- CA125 was elevated in 83% of patients with established ovarian cancer.
- The natural half-life of CA125 in serum was estimated at 4.8 days.
- CA125 levels correlated positively with tumor burden.
- The antigen was not detected in patients with non-Hodgkin lymphoma.
Takeaway
CA125 is a blood test that helps doctors see if ovarian cancer is getting better or worse.
Methodology
The study measured CA125 levels in the serum of 58 patients with ovarian cancer and assessed its correlation with disease status and response to chemotherapy.
Limitations
The specificity of CA125 is poor, particularly in differentiating between ovarian and other adenocarcinomas.
Participant Demographics
Patients with histologically proven ovarian carcinomas, all with known persistent or recurrent disease.
Want to read the original?
Access the complete publication on the publisher's website